Robert D. Hardie - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
10%+ Owner
Signature
/s/ Katherine Denby, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
06 Jul 2021
Net transactions value
+$5,000,000
Form type
4
Filing time
08 Jul 2021, 18:15:57 UTC
Previous filing
30 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Conversion of derivative security +2,950,484 +3289% 3,040,193 06 Jul 2021 See footnote F1, F2
transaction ABOS Common Stock Purchase $5,000,000 +312,500 +10% $16.00 3,352,693 06 Jul 2021 See footnote F2
transaction ABOS Common Stock Conversion of derivative security +657,985 657,985 06 Jul 2021 See footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Series A-1 Preferred Stock Conversion of derivative security $0 -1,634,515 -100% $0.000000* 0 06 Jul 2021 Common Stock 1,634,515 See footnote F1, F2
transaction ABOS Series B Preferred Stock Conversion of derivative security $0 -1,315,969 -100% $0.000000* 0 06 Jul 2021 Common Stock 1,315,969 See footnote F1, F2
transaction ABOS Series B Preferred Stock Conversion of derivative security $0 -657,985 -100% $0.000000* 0 06 Jul 2021 Common Stock 657,985 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert D. Hardie is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
F3 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.